Edgewise Therapeutics, Inc. - Common Stock — Cash Flow (NASDAQ:EWTX) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Cash from operating activities -33.51 M-52.63 M-91.95 M-109.03 M-143.82 M -158.38 M Cash from investing activities -242.23 M-70.58 M102.89 M-184.66 M-32.79 M 166.4 M Cash from financing activities 186.38 M129.64 M53.17 M249.25 M196.09 M 20.89 M Free cash flow -33.51 M-52.63 M-91.95 M-109.03 M-144.07 M -158.83 M

News

Can Camzyos' Growth Offset Bristol Myers' Patent Pressures?

Tracking Baker Brothers Portfolio: Q1 2026 Update

Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?

Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?

Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript

Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy - Slideshow (NASDAQ:EWTX) 2026-06-17

Edgewise Therapeutics Reports Improvements In Heart Drug Trial - Edgewise Therapeutics (NASDAQ:EWTX)

Edgewise Bounds Between Double-Digit Losses And Gain — What's Going On?

Edgewise Stock: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement (EWTX)

Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal

How Edgewise Sweetened Its Coffers By $1.55 Billion, And Removed A Key Overhang

Can Myqorzo Drive Growth for Cytokinetics Amid Competition?